Liminatus Pharma, Inc. Class A Common Stock

NASDAQ: LIMN · Healthcare · Biotechnology

PublicHQ La Palma, CA · OrangeCIK 0001971387Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 14DQ —GM —SS 16

v0.1 · 35/100 weight · pillars only

↑ market scale, Altman-Z · ↓ workforce scale, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$10.2M

Employees

as of 2026-08-24

Market cap

$6.9M

as of 2026-08-24

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$10.2M-$10.2M2025

Operating income-$3.0M-$3.0M2025

Total assets$512.8k$512.8k2025

Liabilities$10.3M$10.3M2025

Equity-$9.8M-$9.8M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Liminatus Pharma, Inc. Class A Common Stock’s financial profile?

Liminatus Pharma, Inc. Class A Common Stock earned -$10.2M in FY2025 net income.

Peers · Healthcare

Aprea Therapeutics, Inc.——Univec, Inc.——Apimeds Pharmaceuticals US, Inc——Curative Biotechnology, Inc.——Curanex Pharmaceuticals Inc Common Stock——Imagion Biosystems Limited——

Neighbors

Orange →

Edwards Lifesciences Corporation$6.1B86A Chipotle Mexican Grill, Inc.$11.9B77B+Rivian Automotive, Inc.$5.4B38D TTM Technologies, Inc.$2.9B73B American Healthcare REIT, Inc.$2.1B56C The Ensign Group, Inc.$5.0B80B+

Key facts

CEOChris Kim

SectorHealthcare

IndustryBiotechnology

HeadquartersLa Palma, CA

ExchangeNASDAQ: LIMN

Employees1

IPO date2025-05-01

Latest filings

8-K2026-08-18 10-Q2026-08-14 8-K2026-08-04 8-K2026-07-30 8-K2026-07-24 DEF 14A2026-07-13 8-K2026-07-06 8-K2026-06-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.